Bibliografía del artículo
1. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 95:261-6, 2000.
2. Bäckström T, Hansson-Malmström Y, Lindhe BA, Cavalli-Björkman B, Nordenström S. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception 46:253-68, 1992.
3. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 54:71-7, 1996.
4. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 72:115-20, 1999.
5. Killick SR, Fitzgerald C, Davis A. Ovarian activity in women taking an oral contraceptive containing 20 microg ethinyl estradiol and 150 microg desogestrel: effects of low estrogen doses during the hormone-free interval. Am J Obstet Gynecol 179:S18-24, 1998.
6. Schlaff WD, Lynch AM, Huges HD, Cedars MI, Smith DL. Manipulation of the pill-free interval in oral contraceptive pill users: the effects on follicular suppression. Am J Obstet Gynecol 190:943-51, 2004.
7. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary--ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 74:100-3, 2006.
8. Holt VL, Cushing-Haugen KL, Daling JR. Oral contraceptives, tubal sterilization, and functional ovarian cyst risk. Obstet Gynecol 102:252-8, 2003.
9. American College of Obstetricians and Gynecologists. Clinical management guidelines for obstetricians-gynecologists: premenstrual syndrome. ACOG practice bulletin 15. Washington, DC, ACOG 2000.
10. Premenstrual dysphoric disorder. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington DC. American Psychiatric Association pp. 771-4, 2000.
11. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28(Suppl.3):1-23, 2003.
12. Sternfeld B, Swindle R, Chawla A, Long S, Kennedy S. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol 99:1014-24, 2002.
13. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106:492-501, 2005.
14. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 5:124-34, 2000.
15. Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. Contraception 71:1-7, 2005.
16. Coffee AL, Kuehl TJ, Sulak PJ. Comparison of scales for evaluating symptoms in women using oral contraceptives. Pharmacotherapy 28:576-83, 2008.
17. Batra P, Harper DM. Recognizing and treating premenstrual dysphoric disorder. JCOM 9:87-98, 2002.
18. Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol 195:935-41, 2006.
19. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 195:1311-9, 2006.
20. Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 75:444-9, 2007.
21. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 68:89-96, 2003.
22. Sulak PJ, Buckley T, Kuehl TJ. Attitudes and prescribing preferences of health care professionals in the United States regarding use of extended-cycle oral contraceptives. Contraception 73:41-5, 2006.